ACADIA Pharmaceuticals Inc. (ACAD) Guidance & Earnings Results

On 2026-08-04 ACADIA Pharmaceuticals Inc. raised guidance: "FY2026 total revenue raised to $1.24-1.30B from $1.22-1.28B; DAYBUE net product sales raised to $480-510M from $460-490M; NUPLAZID net product sales reaffirmed at $760-790M; R&D expense lowered to $355-380M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ACADACADIA Pharmaceuticals Inc.Follow ACAD — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 3.4B
P/E TTM: 8.8
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	FY2026 total revenue raised to $1.24-1.30B from $1.22-1.28B; DAYBUE net product sales raised to $480-510M from $460-490M; NUPLAZID net product sales reaffirmed at $760-790M; R&D expense lowered to $355-380M from $385-410M; SG&A expense $660-700M · full year
6 May 26	Reaffirmed	Total revenue $1.22-1.28B; NUPLAZID $760-790M; DAYBUE $460-490M · full year
25 Feb 26	Raised	FY2026 total revenue guidance $1.22-$1.28B vs FY2025 $1.07B GAAP
13 Jan 26	Reaffirmed	FY2025 net sales > $1B (consistent with prior guidance) · full year
5 Nov 25	Raised	Total revenue guidance raised to $1.070-1.095B from $1.045-1.095B; NUPLAZID raised to $685-695M from $665-690M · full year
6 Aug 25	Raised	FY25 total revenue raised to $1.045-1.095B from $1.030-1.095B; NUPLAZID raised to $665-690M from $650-690M; DAYBUE $380-405M reiterated; R&D $330-350M; SG&A $535-565M. · full year

ACADIA Pharmaceuticals Inc. — questions

What guidance did ACADIA Pharmaceuticals Inc. give?: On 2026-08-04: "FY2026 total revenue raised to $1.24-1.30B from $1.22-1.28B; DAYBUE net product sales raised to $480-510M from $460-490M; NUPLAZID net product sales reaffirmed at $760-790M; R&D expense lowered to $355-380M from $385-410M; SG&A expense $660-700M"
When does ACADIA Pharmaceuticals Inc. report earnings?: ACADIA Pharmaceuticals Inc.'s next earnings report is expected on 2026-11-11.

Every figure on this page comes from ACADIA Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.